Christina Aguilera is arguably one of the biggest pop stars of a generation.
But having been out of the spotlight for several years, she's recently returned with a string of live performances — and a dramatic, rejuvenated look.
Fans first speculated about 43 year-old hitmaker's appearance back in May, following a performance in Mexico in which she seemed to have 'travelled through time', sporting an ultra-slim and youthful look.
Their immediate conclusion was that the Genie in a Bottle singer had fast-tracked her way to dramatic weight loss using injections of blockbuster slimming drug, Ozempic.
'Ozempic ages everyone terribly but it's honestly working wonders for her. She looks incredible,' one fan speculated.
'Best Ozempic results. She looks great', another agreed, with a third adding: 'That's Ozempic Aguilera.'
Now, cosmetic doctors have weighed in, suggesting the singer's new look is indeed likely a result of a 'miracle' weight loss jab, as well as facial surgeries.
London-based aesthetics doctor Dr Jonny Betteridge said he suspects the mother-of-two has undergone a face lift, eyelid surgery and extensive dental work.
'The change in weight in such a short period of time could be attributed to Ozempic use and I also think she would have dissolved all the filler in her face before then undergoing some surgical treatments,' he said.
In a TikTok video seen more than 400,000 times, the former emergency medicine doctor commented on the stark difference between Aguilera's look now, compared to her 'pillow face' appearance seen in 2022.
'A few years ago, she went through a phase of having too much dermal filler which gave a pillow face like appearance,' he said.
'We could predominantly see this in the midface, cheeks and lips.
'As time went on, a combination of too much dermal filler and an overall change in her weight led to this facial fullness.'
Medication such as steroids, used to dampen inflammatory diseases, can also cause a build up of fluid and may lead to swelling in your arms, hands, ankles, legs, face and other parts of the body.
De Betteridge also added: 'If we compare her 18-year-old self to now at 43, the main changes I can immediately see are her nose — it's much sharper and lifted.
'She has more proportionate lips both in relation to the upper and lower lip so we can attribute this to filler and also the dental work as well, with veneers.
'Most notably an upper blepharoplasty to remove excess eyelid skin and I think an endoscopic facelift.'
An upper blepharoplasty, or eyelid lift, is an invasive procedure where surgeons make an incision along the natural eyelid crease to remove excess skin, giving a more taut look free of wrinkles.
Privately, the treatment costs around £4,600 in the UK.
An endoscopic facelift involves making incisions within the hairline and inserting a flexible tube with an attached camera to reposition facial tissues and muscle.
'One of the telltale signs of this procedure is the lifted brow and shape of the eye. It gives a much more sharper look,' Dr Betteridge said.
'Her work is 10 out of 10 and she looks incredible.'
Earlier this month the Diirty singer told Glamour that the internet's speculation over her weight was 'not her business'.
She added: 'I have a maturity now where I just don’t give a f*** about your opinion. I’m not going to take it on.
'It must be your responsibility to take up your space. Other people’s opinions of me are not my business.'
Game-changing injections such as Ozempic and Wegovy, hailed by the likes of Elon Musk and Jeremy Clarkson, are proven to help people lose up to 2st in a matter of months.
Semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro) have been hailed as a monumental breakthrough for obesity treatments.
The pens, taken once a day, trick the brain and make the body think it is full, curbing appetite.
Trials show semaglutide, manufactured by Danish firm Novo Nordisk, helps users lose up to 33lbs (15.3kg) on average in around a year.
Studies of Mounjaro, meanwhile, made by US pharmaceutical giant Eli Lilly, suggest the drug could help obese people lose up to 22.5 per cent of their body weight in 72 weeks.
Semaglutide has been available on the NHS in the UK since 2019, and in the US since 2017, for type 2 diabetics to manage blood sugar levels.
Another semaglutide drug was also approved in Britain for weight loss in 2022, and in the US in 2021, under the brand Wegovy.
But like any medication, the jabs can cause side effects that vary in both frequency and severity.
Reported problems include nausea, constipation, diarrhoea, fatigue, stomach pain, headaches and dizziness.
Bizarre symptoms, such as hair loss, have also been reported among some patients.
Latest NHS data shows 26 per cent of adults in England are obese and a further 38 per cent are overweight but not obese. In the US an estimated 41.9 per cent of adult population are obese.
Despite the hormone mimicking jabs being designed to help overweight patients become healthier, there have also been growing concerns about the number of normal weight and underweight patients taking them for cosmetic reasons.
Some have even needed emergency room care after taking jabs in a bid to become 'beach body ready'.
